71/100B973.07
USD
-7.73
(-0.79%)
Market Open
Last updated: · Delayed 15 min
If you had invested in argenx ago, it would be worth $40,635 today, against $3,367 in SPY and $4,751 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
71/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
argenx key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Growth stock · 10.0/10Growth 10.0 · Value 1.3
- Day range
- 962.20 – 975.84
- 52-week range
- 661.85 – 1,072.75
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 60.46B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 45.13
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.55
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 21.56
- EPS growth forecast (FY2026)
- +254.5%
- Volume
- 1,792
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- -0.02
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 74.6/100Environment 69 · Social 73 · Governance 82
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Karen Massey
- Employees
- 2K
- Website
- argenx.com
- IPO date
- 18 May 2017
argenx earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · H2 FY2026
EPS estimate
7.57 USD
Revenue estimate
3.35B USD
Last quarter · H1 FY2026
EPS7.80Beat +4.8%Revenue2.82BBeat +69.6%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| H2 FY2026 | 7.57 | — | — | +46.14% | 3.35B | — | — | +253.28% | |
| H1 FY2026 | 7.44 | 7.80 | +4.84% | +202.33% | 1.66B | 2.82B | +69.62% | +391.21% | |
| H1 FY2026 | 5.16 | 5.90 | +14.34% | +128.68% | 1.45B | 3.21B | +121.78% | +459.20% | |
| H2 FY2025 | 4.37 | 5.18 | +18.54% | +272.66% | 1.28B | 947.96M | -25.71% | +136.40% | |
| H1 FY2025 | 2.32 | 2.58 | +11.21% | — | 861.83M | 573.24M | -33.49% | +73.82% | |
| H2 FY2024 | 0.10 | 1.39 | +1,290.00% | — | 665.08M | 401.00M | -39.71% | -21.51% | |
| H1 FY2024 | -0.71 | -1.04 | -46.48% | — | 563.91M | 329.79M | -41.52% | +5.47% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 47.22 | — | — | +26.07% | 9.56B | — | — | +17.81% |
| FY2027 | 37.46 | — | — | +36.16% | 8.12B | — | — | +26.49% |
| FY2026 | 27.51 | — | — | +254.49% | 6.42B | — | — | +321.76% |
| FY2025 | 17.65 | 7.76 | -56.04% | +2,117.14% | 4.20B | 1.52B | -63.81% | +108.16% |
| FY2024 | 1.72 | 0.35 | -79.67% | — | 2.16B | 730.79M | -66.20% | -11.27% |
| FY2023 | -4.70 | -1.82 | +61.23% | — | 1.21B | 823.60M | -31.91% | — |
| FY2021 | -7.86 | -3.86 | +50.87% | — | 510.21M | 512.71M | +0.49% | — |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
argenx analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
1,133.33 USD
+16.47%
Analysts' 1-year price targets range from 861.00 to 1,400.00, with an average of 1,133.33.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
18 ratings
| Buy | 16 | |
| Hold | 2 | |
| Sell | 0 |
12-month price target
| Highest target | 1,400.00 |
| Average target | 1,133.33 |
| Lowest target | 861.00 |
| Current price | 973.07 |
argenx valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 45.13
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 35.37
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 13.33
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 7.18
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 39.43
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
60.46B USD
+
Total debt
47.00M USD
−
Cash and short-term investments
5.18B USD
=
Enterprise value
55.32B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
argenx against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Revolution Medicines, Regeneron Pharmaceuticals, Moderna, United Therapeutics, Incyte, and Insmed, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginBelow its median89.1%46.1%92.8%Against its peers: 3 of 7Peers' median 86.6%
- Operating marginHighest in 5 years25.4%-175.4%25.4%Against its peers: 3 of 7Peers' median -66.6%
- Net marginAbove its median31.1%-172.8%38.0%Against its peers: 3 of 7Peers' median -60.1%
- Return on equityHighest in 5 years17.6%-25.2%17.6%Against its peers: 3 of 7Peers' median -4.7%
- Free cash flow marginHighest in 5 years20.3%-235.3%20.3%Against its peers: 4 of 7Peers' median -39.9%
- Revenue growthAt its median89.6%-61.9%2,513.3%Against its peers: 1 of 7Peers' median 5.8%
- Current ratioLowest in 5 years5.235.239.75Against its peers: 3 of 7Peers' median 3.98
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
argenx growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 4.54B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 1.34B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 90.21%
- Operating margin
- 29.36%
- Net margin
- 29.64%
Revenue / Net income
Revenue Net income Net margin
argenx revenue breakdown
By region
FY2025
85.1%United States8.3%Rest Of The World5.0%Japan1.6%China
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 3.53B | 85.1% | +237.7% |
| Rest Of The World | 342.62M | 8.3% | — |
| Japan | 206.84M | 5.0% | +266.5% |
| China | 67.92M | 1.6% | +355.6% |
How argenx makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue4.15B 100.0%
Cost of revenue450.67M 10.9%
Gross profit3.70B 89.1%
Research and development1.36B 32.8%
Selling and administration1.36B 32.7%
Operating income1.05B 25.4%
Net income1.29B 31.1%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
argenx financial health
- Cash and short-term investments
- 5.18B USD
- Total debt
- 47.00M USD
- Net cash
- 5.14B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 1.16B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 5.12
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.01
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 4 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 20.19
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
argenx ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 46.00%
- Institutional holders
- 528 (+29)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 95.42%
Who owns the shares
Institutions 46.0% Others 54.0%
As of 30 Jun 2026
Shares free to trade
Free float 59.28M shares ·95.4% Closely held 2.85M shares ·4.6%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: argenx SE
Sector: Healthcare
Industry: Biotechnology
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.